Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director | June 02, 2026 | June 04, 2026 |
| CONMED CorpCNMD · Entity 4691 | President & CEO | April 01, 2026 | April 02, 2026 |
| MISONIX INCMSON · Entity 132701 | Director | October 29, 2021 | December 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 108,718 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 108,718 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs vested on June 2, 2026.
F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
CONMED Corp
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-04-01 | Direct | 28,145 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 28,145 · Balance 28,145 F1: On March 23rd, 2026, the CONMED Board of Directors approved an additional equity award for the CEO of $1M in target value to be granted in the form of RSUs and scheduled to vest starting April 1st, 2026 over 3-years in three equal annual tranches with a 2-year post-vest holding period to be applied to net after tax shares after each vesting event. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23rd, 2026, the CONMED Board of Directors approved an additional equity award for the CEO of $1M in target value to be granted in the form of RSUs and scheduled to vest starting April 1st, 2026 over 3-years in three equal annual tranches with a 2-year post-vest holding period to be applied to net after tax shares after each vesting event.
MISONIX INC
Report date October 29, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-29 transaction · row 1
1 source rowRow 1 · 2021-10-29 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers"). F2: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. F3: Includes 20,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers").
F2: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.
F3: Includes 20,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:45 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 25,146 | $0.00 | $0.00 |
DisclosureSEC source: 0001627985-26-000002 · wk-form4_1780605943.xml · derivative · entry 3 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,146 Underlying: Class A Common Stock · 25,146 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:45 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001627985-26-000002 · wk-form4_1780605943.xml · derivative · entry 2 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2026. F2 · derivative.expiration_date: The RSUs vested on June 2, 2026. Read SEC document |
| June 02, 2026 Filed Jun 4, 2026 20:45 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001627985-26-000002 · wk-form4_1780605943.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,718 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2026 Filed Apr 2, 2026 20:05 UTC | CONMED Corp CNMD · Entity 4691 | GrantRSUs (Restricted Stock Units) · Derivative | 28,145 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000041 · form4.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,145 Underlying: Common Stock · 28,145 shares Expires 2036-04-01 F1 · derivative.exercise_date: On March 23rd, 2026, the CONMED Board of Directors approved an additional equity award for the CEO of $1M in target value to be granted in the form of RSUs and scheduled to vest starting April 1st, 2026 over 3-years in three equal annual tranches with a 2-year post-vest holding period to be applied to net after tax shares after each vesting event. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 20:47 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 68,258 | $0.00 Strike: $45.79 | $0.00 |
DisclosureSEC source: 0000816956-26-000013 · form4.xml · derivative · entry 2 Beyer Pat · CIK 0001627985 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,258 Underlying: Common Stock · 68,258 shares Expires 2036-03-02 F2 · derivative.exercise_date: The stock options were granted under CONMED Corporation Corporation's 2025 Long-Term Incentive Plan, with the stock options generally vesting in equal amounts over a four-year period with the first 25% of the stock options vesting one year after the grant date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 20:47 UTC | CONMED Corp CNMD · Entity 4691 | GrantRSUs (Restricted Stock Units) · Derivative | 28,800 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000013 · form4.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,800 Underlying: Common Stock · 28,800 shares Expires 2036-03-02 F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of CONMED Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting over a three-year period with the first 33% of the RSUs vesting one year after the grant date, 33% second year and 34% third year. Read SEC document |
| June 03, 2025 Filed Jun 5, 2025 01:29 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 32,282 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000302 · wk-form4_1749086964.xml · derivative · entry 3 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,282 Underlying: Class A Common Stock · 32,282 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:29 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000302 · wk-form4_1749086964.xml · derivative · entry 2 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 2, 2025. F2 · derivative.expiration_date: The RSUs vested on June 2, 2025. Read SEC document |
| June 02, 2025 Filed Jun 5, 2025 01:29 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-25-000302 · wk-form4_1749086964.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:19 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 86,355 | $0.00 Strike: $67.35 | $0.00 |
DisclosureSEC source: 0001127602-25-000752 · form4.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,355 Underlying: Common Stock · 86,355 shares Expires 2035-01-02 F1 · derivative.exercise_date: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:43 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 965 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000303 · wk-form4_1718746992.xml · derivative · entry 2 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 965 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The 965 RSUs vested on June 16, 2024. F2 · derivative.expiration_date: The 965 RSUs vested on June 16, 2024. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:43 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 965 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000303 · wk-form4_1718746992.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:25 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 26,493 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000284 · wk-form4_1718313901.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,493 Underlying: Class A Common Stock · 26,493 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:43 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000265 · wk-form4_1718153013.xml · derivative · entry 2 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 7, 2024. F2 · derivative.expiration_date: The RSUs vested on June 7, 2024. Read SEC document |
| June 07, 2024 Filed Jun 12, 2024 00:43 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-24-000265 · wk-form4_1718153013.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,978 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2024 Filed May 2, 2024 17:03 UTC | CONMED Corp CNMD · Entity 4691 | PurchaseCommon Stock | 3,000 | $68.30 | $204,900.00 |
DisclosureSEC source: 0001127602-24-013824 · form4.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,807 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from 68.29 to 68.40. Full information regarding the number of shares purchased at each separate price will be provided upon request of the commission staff, CONMED or CONMED security holder Read SEC document |
| April 24, 2024 Filed Apr 26, 2024 19:41 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 20,060 | $70.01 Strike: $70.01 | $1,404,400.60 |
DisclosureSEC source: 0001127602-24-013436 · form4.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,060 Underlying: Common Stock · 20,060 shares Expires 2034-04-24 F1 · derivative.exercise_date: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:01 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 44,677 | $0.00 Strike: $79.95 | $0.00 |
DisclosureSEC source: 0001127602-24-008492 · form4.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,677 Underlying: Common Stock · 44,677 shares Expires 2034-03-01 F1 · derivative.exercise_date: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:08 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 965 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000049 · primary_doc.xml · derivative · entry 2 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 965 Underlying: Class A Common Stock · 965 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: 965 RSUs vested on June 16, 2023. The remaining 965 RSUs shall vest and become exercisable on June 16, 2024, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: 965 RSUs vested on June 16, 2023. The remaining 965 RSUs shall vest and become exercisable on June 16, 2024, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:08 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 965 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000049 · primary_doc.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 07, 2023 Filed Jun 8, 2023 22:45 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 30,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000037 · primary_doc.xml · derivative · entry 3 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,400 Underlying: Class A Common Stock · 30,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:45 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000037 · primary_doc.xml · derivative · entry 2 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The RSUs vested on June 6, 2023. F2 · derivative.expiration_date: The RSUs vested on June 6, 2023. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:45 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0001578563-23-000037 · primary_doc.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,613 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 00:08 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 32,212 | $0.00 Strike: $96.16 | $0.00 |
DisclosureSEC source: 0001127602-23-008906 · form4.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,212 Underlying: Common Stock · 32,212 shares Expires 2033-03-01 F1 · derivative.exercise_date: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| June 17, 2022 Filed Jun 23, 2022 00:41 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 16,648 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023642 · doc4.xml · derivative · entry 3 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,648 Underlying: Class A Common Stock · 16,648 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3 · derivative.exercise_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. F3 · derivative.expiration_date: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 16, 2022 Filed Jun 23, 2022 00:41 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 965 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023642 · doc4.xml · derivative · entry 2 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,930 Underlying: Class A Common Stock · 965 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The remaining RSUs shall vest and become exercisable in two approximately equal installments on June 16, 2023 and June 16, 2024, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. F2 · derivative.expiration_date: The remaining RSUs shall vest and become exercisable in two approximately equal installments on June 16, 2023 and June 16, 2024, subject to the Non-Employee Director continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| June 16, 2022 Filed Jun 23, 2022 00:41 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A common stock | 965 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-023642 · doc4.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 22:34 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 55,000 | $0.00 Strike: $144.55 | $0.00 |
DisclosureSEC source: 0001127602-22-008074 · form4.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 13:09 UTC | CONMED Corp CNMD · Entity 4691 | SaleCommon Stock | 6,497 | $149.20 | $969,345.90 |
DisclosureSEC source: 0001127602-21-028423 · form4.xml · nonDerivative · entry 3 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,807 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.02 to $149.52. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 13:09 UTC | CONMED Corp CNMD · Entity 4691 | SaleCommon Stock | 10,550 | $148.47 | $1,566,379.60 |
DisclosureSEC source: 0001127602-21-028423 · form4.xml · nonDerivative · entry 2 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,304 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.00 to $148.92. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 13:09 UTC | CONMED Corp CNMD · Entity 4691 | SaleCommon Stock | 400 | $147.51 | $59,002.00 |
DisclosureSEC source: 0001127602-21-028423 · form4.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,854 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.95 to $147.92. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:59 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionSars (Stock Appreciation Rights) · Derivative | 50,700 | $0.00 Strike: $51.30 | $0.00 |
DisclosureSEC source: 0001127602-21-028140 · form4.xml · derivative · entry 9 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,700 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Plan and generally vest in equal amounts (20%) over a five year period. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:59 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionOptions To Purchase Common Stock · Derivative | 55,300 | $0.00 Strike: $39.87 | $0.00 |
DisclosureSEC source: 0001127602-21-028140 · form4.xml · derivative · entry 8 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 55,300 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:59 UTC | CONMED Corp CNMD · Entity 4691 | Tax withholdingCommon Stock | 33,253 | $146.28 | $4,864,248.84 |
DisclosureSEC source: 0001127602-21-028140 · form4.xml · nonDerivative · entry 7 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,254 Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:59 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 50,700 | $51.30 | $2,600,910.00 |
DisclosureSEC source: 0001127602-21-028140 · form4.xml · nonDerivative · entry 6 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,507 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:59 UTC | CONMED Corp CNMD · Entity 4691 | SaleCommon Stock | 5,589 | $146.14 | $816,748.52 |
DisclosureSEC source: 0001127602-21-028140 · form4.xml · nonDerivative · entry 5 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,807 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.93 to $146.53. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:59 UTC | CONMED Corp CNMD · Entity 4691 | SaleCommon Stock | 16,904 | $145.31 | $2,456,269.53 |
DisclosureSEC source: 0001127602-21-028140 · form4.xml · nonDerivative · entry 4 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,396 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.92 to $145.92. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:59 UTC | CONMED Corp CNMD · Entity 4691 | SaleCommon Stock | 2,789 | $144.50 | $403,002.13 |
DisclosureSEC source: 0001127602-21-028140 · form4.xml · nonDerivative · entry 3 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,300 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.90 to $144.88. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:59 UTC | CONMED Corp CNMD · Entity 4691 | Tax withholdingCommon Stock | 30,018 | $144.62 | $4,341,203.16 |
DisclosureSEC source: 0001127602-21-028140 · form4.xml · nonDerivative · entry 2 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,089 Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:59 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 55,300 | $39.87 | $2,204,811.00 |
DisclosureSEC source: 0001127602-21-028140 · form4.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · President Int'l & Global Ortho 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:20 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 2,895 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-042370 · doc4.xml · derivative · entry 2 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,895 Underlying: Class A Common Stock · 2,895 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F5 · derivative.exercise_date: The restricted stock units shall vest and become exercisable in three equal installments, with the first installment vesting and becoming exercisable on the earlier of (I) the day immediately preceding the date of the Issuer's first annual meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant (such earlier date, the "Installment Vesting Date") and the second and third installments vesting and becoming exercisable on the first and second anniversaries of the Installment Vesting Date, respectively, in teach case subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. F5 · derivative.expiration_date: The restricted stock units shall vest and become exercisable in three equal installments, with the first installment vesting and becoming exercisable on the earlier of (I) the day immediately preceding the date of the Issuer's first annual meeting of stockholders following the date of grant and (ii) the first anniversary of the date of grant (such earlier date, the "Installment Vesting Date") and the second and third installments vesting and becoming exercisable on the first and second anniversaries of the Installment Vesting Date, respectively, in teach case subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. Read SEC document |
| October 29, 2021 Filed Nov 2, 2021 20:20 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 34,906 | Not disclosed Strike: $10.94 | Not disclosed |
DisclosureSEC source: 0000899243-21-042370 · doc4.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,906 Underlying: Class A Common Stock · 34,906 shares Expires 2031-05-14 F2 · price: Pursuant to the Agreement and Plan of Merger, dated as of July 29, 2021 (the "Merger Agreement"), each option to purchase Misonix Inc. ("Misonix") common stock (a "Misonix Option"), whether vested or unvested, that was outstanding immediately prior to the effective time of the transactions contemplated by the Merger Agreement (the "Effective Time"), was converted into an option to acquire the number of shares of Class A common stock of the Issuer (an "Issuer Option") equal to the product of (i) the number of shares of Misonix common stock subject to such Misonix Option immediately prior to the First Effective Time (as defined in the Merger Agreement); by (B) the Option Exchange Ratio (as defined in the Merger Agreement), F3 · price: (Continued from Footnote 2) rounded down to the nearest whole number of shares of the Issuer's Class A common stock, at an exercise price per share equal to the quotient obtained by dividing the per share exercise price of the Misonix Option by the Option Exchange Ratio, rounded up to the nearest whole cent. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| October 29, 2021 Filed Dec 8, 2021 16:42 UTC | MISONIX INC MSON · Entity 132701 | Disposition to issuerCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-21-030842 · ownership.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers"). F2 · shares: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. F3 · shares: Includes 20,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement). F1 · price: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers"). F2 · price: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. F3 · price: Includes 20,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| May 14, 2021 Filed May 18, 2021 11:29 UTC | MISONIX INC MSON · Entity 132701 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $19.09 | $0.00 |
DisclosureSEC source: 0001493152-21-012094 · ownership.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-14 F1 · derivative.exercise_date: Award of Stock Options under the Misonix 2017 Equity Incentive Plan. Stock Options vest in four equal annual installments on the anniversary of the grant date, May 14, 2021. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 00:11 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 46,750 | $0.00 Strike: $122.55 | $0.00 |
DisclosureSEC source: 0001127602-21-009282 · form4.xml · derivative · entry 1 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,750 Underlying: Common Stock · 46,750 shares Expires 2031-03-01 F1 · derivative.exercise_date: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:22 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 55,000 | $0.00 Strike: $97.69 | $0.00 |
DisclosureSEC source: 0001127602-20-008979 · form4.xml · derivative · entry 4 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2030-03-02 F2 · derivative.exercise_date: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:22 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRsus (restricted Stock Units) · Derivative | 725 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008979 · form4.xml · derivative · entry 3 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 725 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:22 UTC | CONMED Corp CNMD · Entity 4691 | Tax withholdingCommon Stock | 341 | $94.64 | $32,272.24 |
DisclosureSEC source: 0001127602-20-008979 · form4.xml · nonDerivative · entry 2 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,807 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 21:22 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-008979 · form4.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:27 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRsus (restricted Stock Units) · Derivative | 725 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009940 · form4.xml · derivative · entry 7 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 725 Underlying: Common Stock · 725 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.